IP Library › Granted Patent US 9,060,981
Granted Patent B2
US 9,060,981 · App. 13/500,753 · Granted Jun 23, 2015

Marker associated with non-alcoholic steatohepatitis

Inventors: Ayumi Sato (Shizuoka, JP); Tsuyoshi Harada (Tokyo, JP); Takashi Yano (Shizuoka, JP); Yoko Wakabayashi (Tokyo, JP)
Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
A61K31/202G01N33/576G01N33/6893G01N2800/044G01N2800/52G01N2800/56G01N2800/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,060,981
App. No.
13/500,753
Granted
Jun 23, 2015
Kind
B2
Abstract

Disclosed is a novel NASH marker for use in a method for detecting NASH or evaluating the severity of NASH, which utilizes at least one factor selected from the group consisting of an IL-1 receptor antagonist, sCD40, HMGB1, sPLA2 group IIA and an sPLA2 activity as the marker. Also disclosed is a method for detecting NASH or evaluating the severity of NASH in a subject, which utilizes the marker.

Claims (9)

1. A method for detecting a non-alcoholic steatohepatitis (NASH) or evaluating seriousness thereof comprising:

(A) measuring an amount and/or activity level of IL-1 receptor antagonist in a biological specimen from a subject as a marker by immunoassay; and

(B) determining if said subject has NASH or evaluating seriousness thereof by comparing the measured value of step (A) with a cut off value, wherein the cut off value is the borderline between positive and negative of a disease, and the cut off value for said IL-1 receptor antagonist is 652 pg/mL.

2. A method for detecting a non-alcoholic steatohepatitis (NASH) or evaluating seriousness thereof comprising:

(A) measuring an amount and/or activity level of sCD40 in a biological specimen from a subject as a marker by immunoassay; and

(B) determining if said subject has NASH or evaluating seriousness thereof by comparing the measured value of step (A) with a cut off value, wherein the cut off value is the borderline between positive and negative of a disease, and the cut off value for said sCD40 is 17.2 pg/mL.

3. A method for detecting a non-alcoholic steatohepatitis (NASH) or evaluating seriousness thereof comprising:

(A) measuring an amount and/or activity level of HMGB1 in a biological specimen from a subject as a marker by immunoassay; and

(B) determining if said subject has NASH or evaluating seriousness thereof by comparing the measured value of step (A) with a cut off value, wherein the cut off value is the borderline between positive and negative of a disease, and the cut off value for said HMGB1 is 3.4 ng/mL.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2021
From: MOCHIDA PHARMACEUTICAL CO., LTD
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 056772/0187 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2012
From: SATO, AYUMI; HARADA, TSUYOSHI; YANO, TAKASHI; WAKABAYASHI, YOKO
To: MOCHIDA PHARMACEUTICAL CO., LTD.
Reel/Frame 028013/0620 →
Priority Claims (1)
JP 2009-239570 · Oct 16, 2009 · national
Continuity (1)
Related Publication 20120231471A1 · Sep 13, 2012